Technology and Innovation最新文献_第2页

Creating the Innovative University 创建创新型大学

IF 0.5

Technology and Innovation Pub Date : 2020-12-01 DOI: 10.21300/21.4.2020.3

R. Hall

引用次数: 3

Innovating the Medical Imaging Course 创新医学影像学课程

IF 0.5

Technology and Innovation Pub Date : 2020-12-01 DOI: 10.21300/21.4.2020.5

Christopher Wiedeman, Huidong Xie, X. Mou, Ge Wang

{"title":"Innovating the Medical Imaging Course","authors":"Christopher Wiedeman, Huidong Xie, X. Mou, Ge Wang","doi":"10.21300/21.4.2020.5","DOIUrl":"https://doi.org/10.21300/21.4.2020.5","url":null,"abstract":"Artificial intelligence (AI) and machine learning (ML), especially deep learning, have generated tremendous impacts throughout our society, including the tomographic medical imaging field. In contrast to computer vision and image analysis, which have been major application examples\u0000 of deep learning and deal with existing images, tomographic medical imaging mainly produces cross-sectional or volumetric images of internal structures from sensor measurements. Recently, deep learning has started being actively developed worldwide for medical imaging, including both tomographic\u0000 reconstruction and image analysis. While medical imaging is a well-established field, in which extensive teaching experience has been accumulated over the past few decades, updating the medical imaging course to reflect AI/ML influence is a new challenge given the rapidly changing landscape\u0000 of AI-based medical imaging, particularly deep tomographic imaging. In the 2019 fall semester, the medical imaging course at Rensselaer Polytechnic Institute was modified to include an AI framework with positive feedback from students. Encouragingly, many students showed a strong motivation\u0000 to learn AI in classes and hands-on projects, as confirmed in their survey reports. In the 2020 fall semester, we improved this course further, incorporating new advances. This article describes our teaching philosophy, practice, and considerations with respect to integrating deep learning,\u0000 tomographic imaging, and hands-on programming to redefine the medical imaging course. Furthermore, given the persistent pandemic, online teaching and examination have become an integral part of higher education. These needs will be addressed as well, with the hope of developing an open course\u0000 in the future.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"202 1","pages":"1-11"},"PeriodicalIF":0.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77036603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issues to Consider Before Asserting A Software Patent 主张软件专利之前要考虑的问题

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.205

M. Greenbaum, S. Herrman

{"title":"Issues to Consider Before Asserting A Software Patent","authors":"M. Greenbaum, S. Herrman","doi":"10.21300/21.3.2020.205","DOIUrl":"https://doi.org/10.21300/21.3.2020.205","url":null,"abstract":"Software patents have garnered a lot of attention in recent years due, at least in part, to the proliferation of software-enabled devices, such as smartphones and tablets, and the use of software to control a range of devices from automobiles to kitchen appliances. Enforcement of software\u0000 patents involves unique legal issues that should be considered before asserting a patent against an accused infringer. A primary issue to consider is whether the patent claims are still patent-eligible under recent changes in the law. Also, certain types of software patents are vulnerable\u0000 to attack in U.S. Patent Office proceedings, but these proceedings are not available unless the patent owner takes step to provoke them. In addition, software inventions are often implemented as method patents, which have unique requirements and restrictions that should be considered. For\u0000 example, steps of a method patent must all be performed by an accused infringer in the United States and must all be performed by the same entity (or under the direction or control of that entity). Where a software invention is not implemented as a method patent, pre-suit damages may not be\u0000 available unless the patentee's own products are properly marked with the patent number, and software has very different requirements for marking than more tangible products. A careful consideration of each of these issues is essential before moving forward with a lawsuit.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"4 1","pages":"205-212"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78279059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infringement Battles: A Case Study Illustrates The Need for Reforms 侵权之战:一个案例研究说明了改革的必要性

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.237

Kevin J. Parker

引用次数: 0

How the U.S. Courts View the Rights of Individual Patentees: A Case Study 美国法院如何看待个人专利权人的权利:一个案例研究

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.229

F. Tehrani

引用次数: 0

The NAI Profile: An Interview With Dr. Dereje Agonafer NAI简介:采访deeje Agonafer博士

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.251

D. Agonafer, Kimberly A. Macuare

引用次数: 0

The NAI Chapter Spotlight: Virginia Commonwealth University 聚焦:弗吉尼亚联邦大学

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.259

I. Metcheva, Kimberly A. Macuare

引用次数: 0

From the USPTO: A New Publication Offers Inventors and Businesses Guidance on Protecting Their Intellectual Property in China 美国专利商标局:一份新出版物为发明人和企业提供了在中国保护其知识产权的指导

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.247

S. Perlmutter

引用次数: 0

An Idea That Has Come of Age—Organized Innovation: a Blueprint for Renewing America's Prosperity 有组织的创新:重振美国繁荣的蓝图

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.243

P. Sanberg, K. Burg

引用次数: 0

Extending Exclusivity for Biopharmaceuticals to Deter Competing Generics: A Review of Strategies, Potential Mitigation, and Similarities to Infringement 延长生物制药专有权以阻止竞争仿制药:策略、潜在缓解和侵权相似之处的回顾

IF 0.5

Technology and Innovation Pub Date : 2020-08-29 DOI: 10.21300/21.3.2020.215

C. Phelps

{"title":"Extending Exclusivity for Biopharmaceuticals to Deter Competing Generics: A Review of Strategies, Potential Mitigation, and Similarities to Infringement","authors":"C. Phelps","doi":"10.21300/21.3.2020.215","DOIUrl":"https://doi.org/10.21300/21.3.2020.215","url":null,"abstract":"Some patents confront infringement—unauthorized use of the inventions in the patent—thus violating the exclusive use intent of the U.S. Constitution's creation of the patent system to encourage innovation. In other situations, the reverse occurs—patent holders seek\u0000 to extend their exclusivity period to prevent competitive entrants. This commonly occurs in biopharmaceutical products markets, where annual revenues on many patented drugs exceed $1 billion per year and (most importantly) where several pathways allow extension of exclusivity. This\u0000 paper reviews the relevant legislation (Bayh-Dole Act, Orphan Drug Act, Hatch-Waxman Act, and Food and Drug Administration (FDA) Modernization Act) as well as the safety and efficacy regulations of the FDA that control marketing of biopharmaceutical products. The paper then assesses methods\u0000 used to extend patent exclusivity—some legal, some clearly illegal, and some with ambiguous legal status—in order to deter generic entrants. These methods include using FDA \"citizen's petitions,\" creating generic equivalents of branded drugs to block other generic entrants, deterring\u0000 potential generic competitors from gaining samples to prove bioequivalence to original formulations, seeking additional patents to extend exclusivity (sometimes for trivial changes), paying potential entrants to delay entry, subdividing the potential patient population to qualify for extensions\u0000 granted by \"orphan drug\" status, and (most recently) selling patents to Native American tribes to prevent challenges to their validity. The paper concludes by discussing remedies—primarily legislative—that could either eliminate these actions and/or clarify their legality. Then\u0000 follows a comparison between these entry-delaying strategies and patent infringement itself.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"43 1 1","pages":"215-227"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77726080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0